Detalles de la búsqueda
1.
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC.
JTO Clin Res Rep
; 5(1): 100622, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38292414
2.
Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study.
Med Oncol
; 41(1): 26, 2023 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129716
3.
Audit of screen failure in 15 randomised studies from a low and middle-income country.
Ecancermedicalscience
; 16: 1476, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36819805
4.
An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings.
Ecancermedicalscience
; 15: 1274, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34567259
5.
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
J Clin Oncol
; 38(2): 124-136, 2020 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31411950
6.
Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.
Oncotarget
; 10(59): 6297-6307, 2019 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31695838
7.
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.
EClinicalMedicine
; 9: 19-25, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31143878
8.
Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study.
Ecancermedicalscience
; 12: 876, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30483356
9.
Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.
Asia Pac J Clin Oncol
; 14(2): e129-e137, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28849623
10.
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
Lung India
; 35(1): 27-30, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29319030
11.
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Chemother Res Pract
; 2017: 8196434, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29201462
12.
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.
Ecancermedicalscience
; 11: 776, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29104613
13.
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
ESMO Open
; 2(1): e000168, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28761735
Resultados
1 -
13
de 13
1
Próxima >
>>